Actively Recruiting
Open-label Study of DPTX3186 to Assess Safety and Pharmacokinetics in Patients with Wnt-Activated Solid Tumors Lacking Other Treatment Options
Led by Dewpoint Therapeutics · Updated on 2026-11-04
60
Participants Needed
8
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a first-in-human clinical trial to study DPTX3186 in adults with solid tumors activated by the Wnt pathway, including cancers such as colorectal, gastric, lung, and triple-negative breast cancer. This study targets patients for whom no other approved treatments exist. The main goals are to evaluate the safety, how the body processes the drug, and initial signs of the drugs activity, while also exploring biological markers that might indicate how well the treatment works. Participants will receive DPTX3186 as a single oral dose once daily in the morning under fasting conditions for four consecutive days followed by a three-day break, completing a 28-day treatment cycle. The study uses a dose escalation approach to determine the appropriate dose and will monitor patients throughout the treatment period. During the trial, participants will be closely monitored for any treatment-related side effects and serious adverse events over up to 36 months. Eligibility includes having measurable tumors confirmed by imaging and good overall health status. The study team will collect information on treatment safety and drug behavior in the body to better understand the drugs potential and guide future research.
CONDITIONS
Brief Title
DPTX3186 in Wnt Pathway Activated Solid Tumors
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here